RxDoctor Payments Data

David Buck, MD

Radiation Oncology · Roanoke, VANPI 1952377194

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (52.0%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. 9 manufacturers reported payments, led by Bayer at 52.5% of the total. Reporting peaked in 2019 at $6,807 and has fallen 72.7% since, to $1,858 in 2025. Among radiation oncology clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$12,812in general payments, 2019–2025

Across 31 payments — averaging $413.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$7K
  • Progenics Pharmaceuticals, Inc.$2K
  • Novartis$2K
  • GE HealthCare$2K
  • GT Medical Technologies, Inc$95
  • Advanced Accelerator Applications$72
  • plus $106 from 3 others
$2,903,869in research payments, 2019–2025

Across 21 payments — averaging $138,279 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novartis$2.9M
  • AstraZeneca$19K
  • E.r. Squibb & Sons, L.L.C.$19K

What the payments were for

  • Consulting fees$6,66352%
  • Speaking & faculty fees$1,98015%
  • Travel & lodging$2,99723%
  • Food & beverage$1,1739%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,812 in reported general payments places this provider in the 95th percentile of 121 radiation oncology providers in Virginia.

See all radiation oncology providers in Virginia

Medicare billing

Part B allowed, 2024
$477,394
Medicare patients
615
Services billed
5,053

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Tolterodine Tartrate ErTolterodine Tartrate11$1,767
Lidocaine Hcl ViscousLidocaine Hcl80$1,715
Mometasone Furoate79$1,375
Tamsulosin Hcl94$775
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen21$399
Dexamethasone11$349
Oxycodone Hcl12$107
Diazepam11$16

Paid to pharmacies, not to this prescriber.

Other radiation oncology in Roanoke

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →